查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1590887

HPV 相关疾病市场：依适应症、治疗方法、分布划分 - 2025-2030 年全球预测

HPV Associated Disorders Market by Indication (AIN, Anal Cancer, Cervical Cancer), Therapy (Prevention, Treatment), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年HPV相关疾病市场价值为93亿美元，预计2024年将达到98.4亿美元，复合年增长率为6.13%，预计2030年将达到141.1亿美元。

HPV相关疾病市场包括人类乳突病毒（HPV）引起的疾病的诊断、治疗和预防，例如子宫颈癌、口咽癌、肛门癌和尖锐湿疣。全球 HPV 感染的高盛行率及其与癌症和非癌症疾病的关联凸显了对该市场的需求，这需要强有力的筛检计划、疫苗和治疗方法。最终使用者是医疗保健提供者、医院、研究机构和寻求预防和治疗解决方案的个别患者。关键的成长要素包括人们对 HPV 相关健康风险的认识提高、疫苗接种计划的扩大、分子诊断技术的进步以及政府和机构对预防措施的大力支持。最新的机会在于人类乳突病毒(HPV)疫苗的广泛使用、更有效的诊断方法的开发以及新兴经济体医疗保健支出的增加。公司可以透过投资下一代疫苗研发、个人化医疗方法以及改善全球 HPV 相关医疗保健资源的获取来抓住这些机会。然而，市场成长受到诸如低收入地区的财务限制、疫苗接种犹豫不决、有关 HPV 及其疫苗的错误讯息以及获得疫苗和医疗保健方面的差异等限制因素的阻碍。挑战还包括监管障碍以及提高筛检和诊断准确性的持续需求。需要创新的领域包括提高疫苗功效和交付、开发照护现场诊断测试以及利用人工智慧来预测和管理 HPV 相关疾病的进展。对市场特征的回顾凸显了技术突破频繁的竞争格局，早期采用创新和策略联盟对于持续成长至关重要。对于公司来说，扩大市场覆盖范围和影响力的建议策略是与政府和非政府卫生组织建立合作伙伴关係，并专注于反虚假资讯的教育宣传活动。

主要市场统计
基准年[2023] 93亿美元
预测年份 [2024] 98.4亿美元
预测年份 [2030] 141.1亿美元
复合年增长率（%） 6.13%

市场动态：针对快速发展的 HPV 相关疾病市场揭示的关键市场见解

供需的动态交互作用正在改变 HPV 相关疾病市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • HPV 相关疾病的盛行率上升
    • 标靶治疗的生长发育
    • 政府积极支持并倡议提高 HPV感染疾病意识
  • 市场限制因素
    • 与 HPV 相关的副作用
  • 市场机会
    • 增加癌症研究的经费和投资
    • HPV 联合检测技术不断进步
  • 市场挑战
    • 患者缺乏对多种治疗方案的认识

波特五力：开拓 HPV 相关疾病市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 HPV 相关疾病市场的外部影响

外部宏观环境因素在塑造 HPV 相关疾病市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解 HPV 相关疾病市场的竞争格局

对 HPV 相关疾病市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵供应商在 HPV 相关疾病市场的绩效评估

FPNV定位矩阵是评估HPV相关疾病市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了 HPV 相关疾病市场的成功之路

HPV 相关疾病市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • HPV 相关疾病的发生率增加
      • 标靶治疗的生长发育
      • 政府积极支持并努力提高人们对 HPV 疾病的认识
    • 抑制因素
      • 与 HPV 相关的副作用
    • 机会
      • 增加癌症研究的经费和投资
      • 同步 HPV 检测的技术进步
    • 任务
      • 患者缺乏对多种治疗方案的认识
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 HPV相关疾病市场（依适应症）

  • 艾因
  • 肛门癌
  • 子宫颈癌
  • 胫
  • 尖圭湿疣

第七章 HPV相关疾病市场治疗

  • 预防
  • 治疗

第八章 HPV相关疾病市场经销商

  • 医院药房
  • 网路药房
  • 零售药房

第九章 美洲HPV相关疾病市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章 亚太地区HPV相关疾病市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲HPV相关疾病市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alembic Pharmaceuticals
  • AstraZeneca plc
  • Bausch Health Companies Inc
  • Biocon Ltd.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company.
  • F. Hoffmann-La Roche Ltd
  • GEA Group Aktiengesellschaft
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals, Inc.
  • JM Huber Corporation
  • Johnson & Johnson Services, Inc.
  • KinoPharma, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
Product Code: MRR-ED54C46E9175

The HPV Associated Disorders Market was valued at USD 9.30 billion in 2023, expected to reach USD 9.84 billion in 2024, and is projected to grow at a CAGR of 6.13%, to USD 14.11 billion by 2030.

The HPV associated disorders market encompasses the diagnosis, treatment, and prevention of diseases caused by the human papillomavirus (HPV), including cervical, oropharyngeal, and anal cancers, as well as genital warts. The necessity of this market is underscored by the high prevalence of HPV infections worldwide and their association with cancerous and non-cancerous conditions, necessitating robust screening programs, vaccines, and therapeutics. The application extends to healthcare providers, hospitals, and research institutions, while the end-use scope covers individual patients seeking preventative and therapeutic solutions. Key growth factors include increasing awareness about HPV-related health risks, expanding vaccination programs, technological advancements in molecular diagnostics, and strong government and organizational support for preventative measures. The latest opportunities lie in the exploitation of HPV vaccines' rising acceptance, ongoing development of more efficient diagnostic methods, and increased healthcare spending in emerging economies. Companies could seize these opportunities by investing in R&D for next-generation vaccines, personalized medicine approaches, and improving access to HPV-related healthcare resources globally. Nonetheless, market growth is hampered by limitations such as financial constraints in low-income regions, vaccine hesitancy, misinformation about HPV and its vaccines, and disparities in vaccine and healthcare access. Challenging factors also include regulatory hurdles and the ongoing need to enhance screening and diagnostic accuracy. Areas ripe for innovation include enhancing the efficacy and delivery of vaccines, developing point-of-care diagnostic tests, and leveraging artificial intelligence to predict and manage HPV-associated disease progression. Insights into the market's nature highlight a competitive landscape with frequent technological breakthroughs, making early adoption of innovations and strategic partnerships crucial for sustained growth. For businesses, fostering collaborations with governmental and non-governmental health organizations and focusing on educational campaigns to combat misinformation are recommended strategies to widen market reach and impact.

KEY MARKET STATISTICS
Base Year [2023] USD 9.30 billion
Estimated Year [2024] USD 9.84 billion
Forecast Year [2030] USD 14.11 billion
CAGR (%) 6.13%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HPV Associated Disorders Market

The HPV Associated Disorders Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of HPV related diseases
    • Growth and development in targeted therapies
    • Proactive government support and initiatives for HPV disorders awareness
  • Market Restraints
    • Adverse effects associated with HPV
  • Market Opportunities
    • Increased funding and investment for cancer research
    • Growing technological advancement in HPV co-testing
  • Market Challenges
    • Lack of patient awareness regarding several treatments options

Porter's Five Forces: A Strategic Tool for Navigating the HPV Associated Disorders Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HPV Associated Disorders Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HPV Associated Disorders Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HPV Associated Disorders Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HPV Associated Disorders Market

A detailed market share analysis in the HPV Associated Disorders Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HPV Associated Disorders Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HPV Associated Disorders Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the HPV Associated Disorders Market

A strategic analysis of the HPV Associated Disorders Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the HPV Associated Disorders Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals, AstraZeneca plc, Bausch Health Companies Inc, Biocon Ltd., Bristol-Myers Squibb Co., Eli Lilly and Company., F. Hoffmann-La Roche Ltd, GEA Group Aktiengesellschaft, GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., J.M. Huber Corporation, Johnson & Johnson Services, Inc., KinoPharma, Inc., Merck & Co., Inc., Novartis AG, and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the HPV Associated Disorders Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across AIN, Anal Cancer, Cervical Cancer, CIN, and Genital Warts.
  • Based on Therapy, market is studied across Prevention and Treatment.
  • Based on Distribution, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of HPV related diseases
      • 5.1.1.2. Growth and development in targeted therapies
      • 5.1.1.3. Proactive government support and initiatives for HPV disorders awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effects associated with HPV
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased funding and investment for cancer research
      • 5.1.3.2. Growing technological advancement in HPV co-testing
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of patient awareness regarding several treatments options
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. HPV Associated Disorders Market, by Indication

  • 6.1. Introduction
  • 6.2. AIN
  • 6.3. Anal Cancer
  • 6.4. Cervical Cancer
  • 6.5. CIN
  • 6.6. Genital Warts

7. HPV Associated Disorders Market, by Therapy

  • 7.1. Introduction
  • 7.2. Prevention
  • 7.3. Treatment

8. HPV Associated Disorders Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas HPV Associated Disorders Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific HPV Associated Disorders Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa HPV Associated Disorders Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alembic Pharmaceuticals
  • 2. AstraZeneca plc
  • 3. Bausch Health Companies Inc
  • 4. Biocon Ltd.
  • 5. Bristol-Myers Squibb Co.
  • 6. Eli Lilly and Company.
  • 7. F. Hoffmann-La Roche Ltd
  • 8. GEA Group Aktiengesellschaft
  • 9. GlaxoSmithKline plc
  • 10. Inovio Pharmaceuticals, Inc.
  • 11. J.M. Huber Corporation
  • 12. Johnson & Johnson Services, Inc.
  • 13. KinoPharma, Inc.
  • 14. Merck & Co., Inc.
  • 15. Novartis AG
  • 16. Pfizer, Inc.

LIST OF FIGURES

  • FIGURE 1. HPV ASSOCIATED DISORDERS MARKET RESEARCH PROCESS
  • FIGURE 2. HPV ASSOCIATED DISORDERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HPV ASSOCIATED DISORDERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HPV ASSOCIATED DISORDERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HPV ASSOCIATED DISORDERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HPV ASSOCIATED DISORDERS MARKET DYNAMICS
  • TABLE 7. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY AIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY ANAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PREVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. HPV ASSOCIATED DISORDERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. HPV ASSOCIATED DISORDERS MARKET, FPNV POSITIONING MATRIX, 2023